SCHEMBL29739717

SCHEMBL29739717

CCONC(=O)c1cccnc1Nc1cc(C)nc(C)c1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 9/20 0.47
▸ RAB9A P51151 6/20 0.47
▸ NPC1 O15118 5/20 0.47
▸ SMN1; SMN2 Q16637 3/20 0.47
▸ AHR P35869 1/20 0.47
▸ MEN1 O00255 11/20 0.46
▸ KMT2A Q03164 11/20 0.46
▸ GAA P10253 2/20 0.46
▸ ALDH1A1 P00352 5/20 0.46
▸ LMNA P02545 3/20 0.45
▸ MAPK1 P28482 2/20 0.44
▸ NPSR1 Q6W5P4 2/20 0.44
▸ POLB P06746 2/20 0.43
▸ HTT P42858 4/20 0.43
▸ PKM P14618 1/20 0.43
▸ DHODH Q02127 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ P2RX7 Q99572 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29685162 0.85 TP53 (0.47) MAPTRAB9ANPC1SMN1; SMN2AHR
SCHEMBL29686396 0.76 PRKCI (0.55) NPC1GAAALDH1A1HTTL3MBTL1
SCHEMBL29684854 0.73 LMNA (0.43) MAPTRAB9ANPC1SMN1; SMN2AHR
SCHEMBL4181112 0.72 MEN1 (0.62) MAPTRAB9ANPC1SMN1; SMN2AHR
SCHEMBL29685491 0.71 GAA (0.44) MAPTRAB9ANPC1SMN1; SMN2AHR
SCHEMBL4167706 0.70 MEN1 (0.58) MAPTRAB9ANPC1MEN1KMT2A
SCHEMBL11833609 0.69 HTT (0.68) MAPTRAB9ANPC1SMN1; SMN2AHR
SCHEMBL26631994 0.69 HTT (0.54) MAPTRAB9ANPC1SMN1; SMN2AHR
SCHEMBL26742261 0.68 HTT (0.56) MAPTRAB9ANPC1SMN1; SMN2AHR
SCHEMBL12478850 0.68 HTT (0.53) RAB9ANPC1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240101548-A1 HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD (CN) 2024-03-28 — — US claimed
EP-4257587-A1 HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shenzhen Chipscreen Biosciences Co., Ltd. (CN) 2023-10-11 — — EP claimed
CN-116283954-A Hydroxamate compound, preparation method and application thereof 深圳微芯生物科技股份有限公司 2023-06-23 — — CN claimed
CN-114901656-A Hydroximic acid ester compound, preparation method and application thereof 深圳微芯生物科技股份有限公司 2022-08-12 — — CN claimed
US-20240101548-A1 HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD (CN) 2024-03-28 — — US disclosed
EP-4257587-A1 HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shenzhen Chipscreen Biosciences Co., Ltd. (CN) 2023-10-11 — — EP disclosed
CN-116283954-A Hydroxamate compound, preparation method and application thereof 深圳微芯生物科技股份有限公司 2023-06-23 — — CN disclosed
CN-114901656-B Hydroximic acid ester compound, preparation method and application thereof 深圳微芯生物科技股份有限公司 2023-04-07 — — CN disclosed
CN-114901656-A Hydroximic acid ester compound, preparation method and application thereof 深圳微芯生物科技股份有限公司 2022-08-12 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240101548-A1 HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF TYK2, WEE2, WEE1 MAPT 2840/4885RAB9A 4737/4885NPC1 4175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback